Aduhelm Approval Greeted With Joy, Concern in Alzheimer’s Community

Aduhelm Approval Greeted With Joy, Concern in Alzheimer’s Community

296940

Aduhelm Approval Greeted With Joy, Concern in Alzheimer’s Community

A new treatment for people with Alzheimer’s disease — the first approved by the U.S. Food and Drug Administration (FDA) in nearly 20 years — will be available soon in the U.S. But the reception being given to Aduhelm (aducanumab) is mixed. Some patients and caregivers welcome the news after years of repeat clinical trial failures and rejections.  Phil Gutis receiving an Aduhelm infusion in the ENGAGE trial. (Photo courtesy of Phil Gutis) “I was relieved and…

You must be logged in to read/download the full post.